Login
Lexicon Pharmaceuticals NASDAQ: LXRX
The orally-delivered small molecule drug candidates under development by Lexicon Pharmaceuticals comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes
| Name | Lexicon Pharmaceuticals |
| Ticker | LXRX |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
| Price | 1.42 |
| 52W Low/High | 1.42 / 5.15 |
| Market cap | 152 M |
| 1Y Total Return |
-55.63%
Weak |
| 1Y Volatility |
73.95%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
The orally-delivered small molecule drug candidates under development by Lexicon Pharmaceuticals comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes
Details
| Ticker | LXRX |
| Name | Lexicon Pharmaceuticals |
| ISIN | US5288723027 |
| CUSIP | 528872302 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 10/19/20
| Close Price | 1.42 |
| 52W Low/High | 1.42 / 5.15 |
| Market cap | 152 M |
| 1Y Total Return |
-55.63%
Weak |
| 1Y Volatility |
73.95%
More Risk |
| Beta | 0.99 |
| PE (trailing) |
5.92
Low |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 12.3% |
| Cash from Op. / Cur. Liabilities | 1.00 |
| Diluted Earnings / Share | 0.24 |
| ROE | - |
| ROIC | 29.8% |
| Price / Revenue | 0.5 |
| Price / Book | -14.2 |
| Price / CF | 1.6 |
| Current Ratio | 2.5 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
320
|
43
|
101
|
77
|
160
|
24
|
|
| Gross Profit |
318
|
40
|
98
|
76
|
160
|
24
|
|
| R&D |
180
|
51
|
156
|
149
|
139
|
86
|
|
| EBITDA |
58
|
-65
|
-116
|
-128
|
-14
|
-94
|
|
| Operating Income |
50
|
-71
|
-122
|
-133
|
-11
|
-95
|
|
| Net Income exc. Extra |
39
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
107
|
106
|
106
|
105
|
104
|
104
|
|
| EPS exc. Extra |
0.24
|
-0.85
|
-1.23
|
-1.23
|
-0.22
|
-1.11
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
323
|
233
|
333
|
364
|
558
|
416
|
|
| Cash, Eq & Invt ShortTerm |
202
|
106
|
210
|
231
|
429
|
282
|
|
| Total Current Assets |
246
|
122
|
220
|
247
|
439
|
314
|
|
| Total Non-Current Assets |
76
|
111
|
113
|
116
|
119
|
102
|
|
| Intangibles |
63
|
94
|
96
|
97
|
98
|
98
|
|
| Total Liabilities |
333
|
298
|
338
|
257
|
341
|
184
|
|
| Total Current Liabilities |
98
|
22
|
81
|
133
|
131
|
44
|
|
| Long Term Debt |
236
|
276
|
257
|
124
|
210
|
141
|
|
| Shareholder equity |
-11
|
-65
|
-5
|
106
|
217
|
231
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
98
|
-102
|
-167
|
-202
|
149
|
-81
|
|
| Depreciation |
4
|
4
|
4
|
3
|
1
|
1
|
|
| Cash from Investing |
-20
|
100
|
6
|
190
|
-118
|
-221
|
|
| Capex |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Financing |
-2
|
-2
|
146
|
4
|
-2
|
284
|
|
| Stock Issued |
-1
|
-1
|
2
|
7
|
0
|
202
|
|
| Debt (LT) Issued |
-1
|
-1
|
144
|
-2
|
-2
|
82
|
|
| Free Cash Flow |
143
|
-21
|
-159
|
129
|
-73
|
-298
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
12.3%
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
194.2%
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
2.5
|
5.5
|
2.7
|
1.9
|
3.4
|
7.2
|
|
| Financial Leverage D/E |
-
|
-
|
-
|
0.95
|
0.47
|
0.46
|
|
| Return on Capital Avg |
29.8%
|
-31.3%
|
-53.1%
|
-26.5%
|
-4.0%
|
-35.3%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available